Dec 10
|
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
|
Dec 10
|
12 Healthcare Stocks Billionaires Like the Most
|
Dec 10
|
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.60
|
Dec 9
|
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
|
Dec 8
|
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
|
Dec 8
|
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
|
Dec 7
|
12 Biggest Financial Scandals in US History
|
Dec 7
|
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
|
Dec 7
|
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
|
Dec 7
|
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
|
Dec 6
|
Bristol Myers Squibb Announces Dividend Increase
|
Dec 6
|
Hedge Funds are Betting on These 14 Sliding Stocks
|
Dec 6
|
15 Best Safe Dividend Stocks For 2024
|
Dec 6
|
Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review
|
Dec 5
|
3 Dirt Cheap Stocks That Could Skyrocket
|
Dec 5
|
12 Best Healthcare Dividend Stocks To Buy Now
|
Dec 5
|
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
|
Dec 5
|
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
|
Dec 1
|
Bristol Myers Squibb CEO Chris Boerner Buys Up Stock
|
Dec 1
|
Insider Buying: CEO Christopher Boerner Acquires Shares of Bristol-Myers Squibb Co
|